氟维司群治疗激素受体阳性晚期乳腺癌的疗效和安全性分析  

Efficacy and safety of fulvestrant for treating patients with hormone receptor positive advanced breast cancer

作　　者：刘巧园 陆永奎[1] 刘燕[1] 农丽[1] 钟武宁 王涵[1] 段丽霞 Liu Qiaoyuan;Lu Yongkui;Liu Yan;Nong Li;Zhong Wuning;Wang Han;Duan Lixia(Department of Internal Breast Neoplasm,The Affiliated Tumor Hospital of Guangxi Medical University)

机构地区：[1]广西医科大学附属肿瘤医院乳腺肿瘤内科,南宁530021

出　　处：《重庆医科大学学报》2021年第1期79-84,共6页Journal of Chongqing Medical University

基　　金：国家自然科学基金地区科学基金资助项目(编号:81560468);国家自然科学基金青年资助项目(编号:81602315);广西医疗卫生适宜技术开发与推广应用资助项目(编号:S201635);广西壮族自治区卫生厅资助项目(编号:Z2013428)。

摘　　要：目的:探讨氟维司群治疗激素受体(hormone receptor,HR)阳性晚期乳腺癌患者的临床疗效和安全性。方法:收集2015年1月至2019年6月就诊于广西医科大学附属肿瘤医院的80例经氟维司群治疗的HR阳性晚期乳腺癌患者临床资料,并对氟维司群的临床疗效、影响因素和不良反应进行回顾性分析。结果:中位随访时间为6.7(2.0,35.6)个月,中位治疗周期为7(2,28)个周期,患者的无进展生存时间(progression-free survival,PFS)为9.3个月(95%CI=4.64~13.96);客观缓解率(objective response rate,ORR)为2.5%,临床获益率(clinical benefit rate,CBR)为40.0%。COX多因素分析显示,患者的PFS与既往接受姑息化疗的线数有关[HR=2.18(1.55,3.08),P=0.000]。本组患者使用氟维司群后整体安全性良好,未出现Ⅲ级及以上不良反应,且未发生治疗相关性死亡。结论:500 mg氟维司群治疗激素受体阳性晚期乳腺癌患者的临床疗效显著,安全性良好。Objective:To investigate the efficacy and safety of fulvestrant for treating patients with hormone receptor(HR)positive advanced breast cancer.Methods:Clinical data of 80 patients with HR positive advanced breast cancer who were treated with fulvestrant in our hospital from January 2015 to June 2016 were collected.The clinical efficacy of fulvestrant,influencing factors and adverse effect were evaluated.Results:The median follow-up was 6.7 months(2.0,35.6 months),median treatment cycle was 7 cycles(2,28 cycles),median progression free survival(PFS)was 9.3 months(95%CI=4.64-13.96),objective response rate(ORR)was 2.5%and clinical benefit rate(CBR)was 40.0%.COX multivariate analysis indicated that PFS was correlated with previous lines of chemotherapy[HR=2.18(1.55,3.08),P=0.000].Conclusion:Fulvestrant of 500 mg has a favorable efficacy in patients with HR positive advanced breast cancer,with good safety.

关 键 词：氟维司群 激素受体阳性 内分泌治疗 晚期乳腺癌 

分 类 号：R737.9[医药卫生—肿瘤]